Product nameAnti-ADA antibody
See all ADA primary antibodies
DescriptionRabbit polyclonal to ADA
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Human
Predicted to work with: Cow
Synthetic peptide within Human ADA aa 100-150. The exact sequence is proprietary.
Database link: P00813
- WB: Jurkat whole cell lysate. IP: Jurkat whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab264378 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 41 kDa.|
|IP||Use at 2-10 µg/mg of lysate.|
FunctionCatalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.
Tissue specificityFound in all tissues, occurs in large amounts in T-lymphocytes and, at the time of weaning, in gastrointestinal tissues.
Involvement in diseaseDefects in ADA are the cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-negative due to adenosine deaminase deficiency (ADASCID) [MIM:102700]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. ADA-SCID is an autosomal recessive form accounting for about 50% of non-X-linked SCIDs. ADA deficiency has been diagnosed in chronically ill teenagers and adults (late or adult onset). Population and newborn screening programs have also identified several healthy individuals with normal immunity who have partial ADA deficiency.
Sequence similaritiesBelongs to the adenosine and AMP deaminases family.
Cellular localizationCell membrane. Cell junction. Cytoplasmic vesicle lumen. Cytoplasm. Colocalized with DPP4 at the cell junction in lymphocyte-epithelial cell adhesion.
- Information by UniProt
- ada antibody
- ADA_HUMAN antibody
- ADA1 antibody
All lanes : Anti-ADA antibody (ab264378) at 0.1 µg/ml
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
Lane 3 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate
Lysates/proteins at 50 µg per lane.
Developed using the ECL technique.
Predicted band size: 41 kDa
Exposure time: 3 seconds
Lysates prepared in NETN lysis buffer.
ADA was immunoprecipitated from Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) using ab264378 at 6 μg per reaction. Western blot was performed on the immunoprecipitates using ab264378 at 0.4 μg/ml.
Lane 1: ab264378 IP in Jurkat whole cell lysate.
Lane 2: Control IgG IP in Jurkat whole cell lysate.
Exposure time: 3 seconds.
Lysates prepared in NETN lysis buffer.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab264378 has not yet been referenced specifically in any publications.